Gilead's HIV franchise gains momentum as Yeztugo ramps up, Biktarvy leads treatment and new pipeline advances strengthen growth prospects.

GILD beats Q2 revenue estimates as HIV sales fuel growth, while acquisition charges cause a loss. Higher HIV guidance and pipeline progress support momentum.

Ionis beats Q2 revenues and earnings estimates as commercial growth offsets tough comparisons, while reaffirming its 2026 outlook.

MRNA is likely to face a key Q2 test as investors await results, FDA updates on mRNA-1010 and commercialization plans that could shape its post-COVID growth.

GSK beats Q2 earnings and revenue estimates, reaffirms 2026 guidance and unveils a new cost-saving plan.

GILD heads into Q2 earnings with HIV franchise strength, rising Yeztugo expectations and oncology progress, even as Cell Therapy faces competitive pressure.

Glaxo (GSK) delivered earnings and revenue surprises of +7.09% and +4.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Intel's AI infrastructure push, Dell's AI server boom and Progressive's premium growth highlight the latest top research reports and key opportunities.

GILD's HIV franchise gains momentum with strong Biktarvy and Descovy demand, Yeztugo growth and a promising pipeline targeting long-term expansion.

GSK secures early FDA approval for Jideytro, its first lung cancer therapy, backed by strong ARROS-1 data, and strengthens its precision oncology portfolio.